人肝脏型脂肪酸结合蛋白(L-FABP)ELISA Kit产品类型:ELISA Kit产品名称:人肝脏型脂肪酸结合蛋白(L-FABP)ELISA Kit英文名称:Human Liver Type Fatty Acid Binding Protein(L-FABP) ELISA KIT货号:YB-E13455h别名:FABPL, L-FABP, Fatty acid-binding protein, liver规格:96T种属:Human待测物名称:fatty acid binding protein 1, liver缩写:FABP1蛋白功能1:Transport蛋白功能3:Transport检测范围:31.2 pg/ml-2000pg/ml灵敏度:7.8 pg/ml反应时间:1-5h所需样本体积:50-100ul检测波长:450 nmThis assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for L-FABP has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any L-FABP present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for L-FABP is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of L-FABP bound in the initial step. The color development is stopped and the intensity of the color is measured.

近日，来自美国麻省理工学院的研究人员在著名国际学术期刊nature在线发表了一项最新研究进展，他们发现PPARa激动剂对于治疗红细胞生成素抵抗性贫血症具有重要作用。 许多急性和慢性贫血症，包括红细胞溶解，脓毒病以及遗传性骨髓衰竭如Diamond-Blackfan贫血，对于红细胞生成素（Epo）治疗并不能获得比较好的治疗效果，其中的原因主要是由于响应Epo处理的克隆形成单元红系祖细胞（CFU-E）数目过少或对与Epo处理不够敏感，不足以维持红细胞产生。对这些贫血病的治疗需要一种能够作用于红细胞形成早期阶段的药物，增强Epo敏感性的CFU-E祖细胞形成。 在之前一项研究中，研究人员证明糖皮质激素能够特异性刺激一种早期红系祖细胞--BFU-E的自我更新，从而增加终末分化的红细胞的产生。而在该项研究中，研究人员发现利用PPARa激动剂GW7647和菲诺贝特激活PPARa能够与糖皮质激素受体协同促进BFU-E的自我更新。经过一段时间处理，这些激动剂能够大大增加成熟红细胞的产生。虽然PPARa敲除小鼠并没有表现出造血功能的变化，但利用PPARa激动剂处理PPARa敲除小鼠并不能恢复苯肼诱导的急性溶血性贫血，而野生型小鼠可以得到恢复。研究人员利用BFU-E细胞进行机制研究，发现PPARa能够与糖皮质激素受体共同占据部分染色质的转录因子结合位点，利用PPARa激动剂进行处理会促使更多的PPARa募集到糖皮质激素受体临近为止，促进糖皮质激素受体依赖性的BFU-E 自我更新。 这项研究发现PPARa激动剂在刺激早期红系祖细胞自我更新方面具有重要作用，表明PPARa激动剂可能会提高皮质甾醇在治疗Epo抵抗性贫血症方面的治疗效果，因此这项研究具有重要意义yb-2686E 兔核因子κB亚基p65亲和肽(NF-κB p65)ELISA kit 血清/组织/尿液yb-2687E 兔粒细胞集落刺激因子(G-CSF)ELISA kit 血清/组织/尿液yb-2688E 兔血清淀粉样蛋白A(SAA)ELISA kit 血清/组织/尿液yb-2689E 兔结合珠蛋白/触珠蛋白(Hpt/HP)ELISA kit 血清/组织/尿液yb-2690E 兔子α2抗纤溶酶(α2-AP)ELISA kit   血清/组织/尿液yb-2691E 兔子纤溶酶原(Plg)ELISA kit   血清/组织/尿液yb-2692E 兔骨形成蛋白(BMPs)ELISA kit   血清/组织/尿液yb-2693E 兔骨保护素(OPG)ELISA kit   血清/组织/尿液yb-2694E 兔胰淀素(Amylin)ELISA kit   血清/组织/尿液yb-2695E 兔心肌肌钙蛋白Ⅰ(cTn-Ⅰ)ELISA kit 血清/组织/尿液yb-2696E 兔核因子κB受体活化因子配基(RANKL)ELISA kit   血清/组织/尿液yb-2697E 兔乳铁传递蛋白/乳铁蛋白(LF/LTF)ELISA kit   血清/组织/尿液yb-2698E 兔心肌特异性肌钙蛋白T(cTnT)ELISA kit   血清/组织/尿液yb-2699E 兔溶菌酶(LZM)ELISA kit   血清/组织/尿液yb-2700E 兔子催乳素(PRL)ELISA kit 血清/组织/尿液yb-2701E 兔子促黄体激素(LH)ELISA kit   血清/组织/尿液yb-2702E 兔抗脑组织抗体(ABAb)ELISA kit   血清/组织/尿液yb-2703E 兔p53(p53)ELISA kit   血清/组织/尿液yb-2704E 兔Bcl-2相关X蛋白(BAX)ELISA kit   血清/组织/尿液yb-2705E 兔阿霉素(ADR)ELISA kit 血清/组织/尿液yb-2706E 兔基质金属蛋白酶2/明胶酶A(MMP-2/Gelatinase A)ELISA kit 血清/组织/尿液yb-2707E 兔抑瘤素M(OSM)ELISA kit 血清/组织/尿液yb-2708E 兔血管生成素2(ANG-2)ELISA kit 血清/组织/尿液yb-2709E 兔血管紧张素Ⅱ(ANG-Ⅱ)ELISA kit 血清/组织/尿液yb-2710E 兔可溶性凋亡相关因子(sFAS/Apo-1)ELISA kit   血清/组织/尿液yb-2711E 兔6酮前列腺素F1a(6-keto-PGF1a)ELISA kit 血清/组织/尿液yb-2712E 兔血栓素B2(TXB2)ELISA kit 血清/组织/尿液yb-2713E 兔血管内皮细胞粘附分子1(VCAM-1/CD106)ELISA kit 血清/组织/尿液yb-2714E 兔血纤蛋白原(Fbg)ELISA kit 血清/组织/尿液yb-2715E 兔子D二聚体(D2D)ELISA kit 血清/组织/尿液yb-2716E 兔子白介素1可溶性受体I (IL-1sR Ⅰ)ELISA kit 血清/组织/尿液yb-2717E 兔钩端螺旋体IgG(Lep IgG)ELISA kit 血清/组织/尿液yb-2718E 兔凝血酶原片段F1+2(F1+2)ELISA kit 血清/组织/尿液yb-2719E 兔子肾上腺髓质素(ADM)ELISA kit 血清/组织/尿液yb-2720E 兔子可溶性血管内皮细胞蛋白C受体(sEPCR)ELISA kit 血清/组织/尿液yb-2721E 兔脂蛋白α(Lp-α)ELISA kit   血清/组织/尿液yb-2722E 兔载脂蛋白E(Apo-E)ELISA kit   血清/组织/尿液

近日，来自西班牙的科学家Carlos López-Otín在国际学术期刊发表了一篇综述性文章，就线粒体蛋白酶在人类健康，衰老和疾病中的新作用进行了总结讨论。 作者在文中指出，最近一些关于线粒体生物学的研究发现调节线粒体功能的蛋白水解酶存在高度多样性和复杂性。科学家们将线粒体蛋白酶根据其功能和细胞内定位进行了归类，将人类基因组编码的人类线粒体降解组定义为一个完整的线粒体蛋白酶组。虽然线粒体蛋白酶在执行蛋白降解功能方面存在非特异性，但其催化的蛋白质水解反应对于线粒体功能，完整性和平衡具有重要作用，其中包括蛋白质合成，蛋白质量控制，线粒体生成和动态变化，线粒体自噬和细胞凋亡。线粒体蛋白酶发生损伤或功能失调与衰老以及多种病理过程如神经退行性紊乱，代谢综合征和癌症具有密切联系。对线粒体蛋白水解及其调节过程有一个更好的了解能够促进对人类寿命和健康状态的研究。 在该文章中，作者首先从线粒体蛋白酶的结构和催化功能多样性谈起，对线粒体蛋白酶的不同分类进行了详细总结概括。随后，作者详述了线粒体蛋白酶的新功能，包括在蛋白转运，加工和激活，蛋白品质控制，线粒体生成，线粒体应激响应，线粒体动态变化，线粒体自噬，细胞凋亡等方面发挥的新作用。最后，作者对线粒体蛋白酶水解与衰老和相关疾病发生的关系进行了总结概述，并对未来研究方向和需要解决的问题进行了展望。 总的来说，作者在这篇文章中详细总结了目前在线粒体蛋白酶研究方面所取得的最新进展，对于线粒体与人类衰老，健康和疾病的关系研究具有重要指导意义yb-2654E 人亮氨酰氨基肽酶(LAP)ELISA试剂盒 血清/组织/尿液yb-2655E 人链激酶(SK)ELISA试剂盒 血清/组织/尿液yb-2656E 人核糖核酸酶(RNASE)ELISA试剂盒 血清/组织/尿液yb-2657E 人过氧化脂质/乳过氧化物酶(LPO)ELISA试剂盒 血清/组织/尿液yb-2658E 人芳基硫酸酯酶A(ASA)ELISA试剂盒 血清/组织/尿液yb-2659E 人对氧磷酶(PON)ELISA试剂盒 血清/组织/尿液yb-2660E 人丙酮酸激酶(PK)ELISA试剂盒 血清/组织/尿液yb-2661E 人半乳糖6硫酸酯酶(Gal-6S)ELISA试剂盒 血清/组织/尿液yb-2662E 人艾杜糖硫酸酯酶(IDS)ELISA试剂盒 血清/组织/尿液yb-2663E 人β葡萄糖醛酸苷酶(βGD)ELISA试剂盒 血清/组织/尿液yb-2664E 人β葡糖苷酶(β-glucosidase)ELISA试剂盒 血清/组织/尿液yb-2665E 人β内酰胺酶(β-lactamase)ELISA试剂盒 血清/组织/尿液yb-2666E 人β甘露糖苷酶(β Manase)ELISA试剂盒 血清/组织/尿液yb-2667E 人β半乳糖苷酶(βGAL)ELISA试剂盒 血清/组织/尿液yb-2668E 人αL艾杜糖苷酸酶(IDUA)ELISA试剂盒 血清/组织/尿液yb-2669E 人α2抗纤溶酶(α2-AP)ELISA试剂盒 血清/组织/尿液yb-2670E 人N-乙酰-β-D-氨基葡萄糖苷酶(NAG)ELISA试剂盒 血清/组织/尿液yb-2671E 人L苯丙氨酸解氨酶(PAL)ELISA试剂盒 血清/组织/尿液yb-2672E 人5核苷酸酶(5-NT)ELISA试剂盒 血清/组织/尿液yb-2673E 人1,3-βD葡葡糖苷酶(1,3-βD-Glu)ELISA试剂盒 血清/组织/尿液yb-2674E 人肌酸激酶(CK)ELISA试剂盒 血清/组织/尿液yb-2675E 人靶向核糖核酸酶(TR)ELISA试剂盒 血清/组织/尿液yb-2676E 人蛋白激酶C(PKC)ELISA试剂盒 血清/组织/尿液yb-2677E 人醛缩酶(ALD)ELISA试剂盒 血清/组织/尿液yb-2678E 人L-乳酸脱氢酶(L-LDH)ELISA试剂盒 血清/组织/尿液yb-2679E 人酸性神经鞘磷脂酶(ASM)ELISA试剂盒 血清/组织/尿液yb-2680E 人花生四烯酸5脂加氧酶(ALOX-5)ELISA试剂盒 血清/组织/尿液yb-2681E 人5脂加氧酶(5-LO/LOX)ELISA试剂盒 血清/组织/尿液yb-2682E 人腺苷酸环化酶1(AC-1)ELISA试剂盒 血清/组织/尿液yb-2683E 人可溶性腺苷酸环化酶(sAC)ELISA试剂盒 血清/组织/尿液yb-2684E 人鸟氨酸脱羧酶(ODC)ELISA试剂盒 血清/组织/尿液yb-2685E 人蛋白酪氨酸激酶(PTK/CD115)ELISA试剂盒 血清/组织/尿液

胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒适用生物     Homo sapiens (Human，人)    胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒   检测范围     0.156-10ng/mL     灵敏度     0.062ng/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法   胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒规格     96T    ELISA Kit for Thymidine Phosphorylase (TP)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒 Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.062ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Thymidine Phosphorylase (TP). No significant cross-reactivity or interference between Thymidine Phosphorylase (TP) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Thymidine Phosphorylase (TP) and the recovery rates were calculated by comparing the measured value to the expected amount of Thymidine Phosphorylase (TP) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     78-95     82    EDTA plasma(n=5)     83-99     96    heparin plasma(n=5)     92-99     95    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Thymidine Phosphorylase (TP) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Thymidine Phosphorylase (TP) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Thymidine Phosphorylase (TP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     85-102%     98-105%     83-104%     80-96%    EDTA plasma(n=5)     92-101%     90-101%     88-102%     95-104%    heparin plasma(n=5)     94-102%     89-97%     85-101%     99-105%    StabilityThe stability of kit is determined胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒 by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this 胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Thymidine Phosphorylase (TP). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Thymidine Phosphorylase (TP). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Thymidine Phosphorylase (TP), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Thymidine Phosphorylase (TP) in the samples 胸腺嘧啶核苷磷酸化酶(TP)检测试剂盒is then determined by comparing the O.D. of the samples to the standard curve.

炎症反应一般由血管化组织的损伤引起，它能够通过清除微生物，愈合伤口实现机体的稳态控制。然而，不受控制的炎症反应也能够引发机体的病变。因此，我们需要对炎症反应中的信号传导机制有系统的了解。然而，最大的难题在于炎症组织内部的信号错综复杂，牵一发而动全身，所以要想从中找出某一条清晰的线索是比较困难的。对于中性粒细胞相应炎性刺激的迁移过程，McDonald等人对其中的每一步都做了详细的研究。首先，他们利用活体成像技术实时地观察了组织受损的小鼠的免疫反应。他们对小鼠的肝脏表面做了高温刺激使其发生坏死性凋亡。他们发现中性粒细胞在损伤发生后的一个小时之内就迁移到了炎症反应部位。第一眼看上去，炎症反应部位像是均质化的，上面既有活细胞也有死细胞。好像中性粒细胞没有选择反应对象的余地。然而这个看上去均质化的部位含有非常复杂的细胞因子，它们能直接或间接作用于中性粒细胞。在炎症部位，受损的细胞会释放一类可溶性的分子，叫做damage-associated molecular patterns (DAMPs)。DAMP包括ATP,甲酰化多肽，热休克蛋白（HSP），染色质，半乳糖凝集素等。周围的巨噬细胞可以以多种方式响应DAMP的信号，比如通过释放趋化因子来进一步扩大炎症反应的强度。最终这一效应导致血管表面高表达用于吸附淋巴细胞的粘附性分子。在粘附分子的的作用下，淋巴细胞越过血管的屏障，到达受损的组织附近。一些粘附分子在此过程中起了重要的作用，比如beta-2 integrin在减慢淋巴细胞在血管中的流动速度，提高其粘附几率的作用。趋化因子一方面可以用于激活淋巴细胞，另一方面也能通过形成化学浓度梯度吸引淋巴细胞向指定的部位迁移。之后，作者通过遗传学或药物阻断的方式详细地分离了在中性粒细胞迁移过程中的各类信号。对于DAMP来说，死亡细胞释放的ATP是一类关键信号，它能够激活局部巨噬细胞的嘌呤能受体，激活胞内的NLRP3炎症小体以及促进IL-1beta的分泌。IL-1beta能够促进血管表皮细胞表达粘附性分子ICAM-1，从而增强MAC-1介导的对中性粒细胞的粘附作用。之后，被粘附的中性粒细胞沿着窦状血管爬附，同时受到趋化因子浓度梯度的吸引向坏死区域移动。这一信号依赖于中性粒细胞表面的趋化因子受体CXCR2。尽管炎症部位产生很多的趋化引起浓度梯度，然而中性粒细胞却只对其中很少的一些有反应，而且随着向目标位置不断移动，中性粒细胞所偏好的趋化因子也会发生转变。这个问题至今没有明确的解释。其中一个可能是：在早期的迁移过程中，中性粒细胞主要受到局部巨噬细胞分泌的炎症信号影响，而在到达“边境”区域时，中性粒细胞主要靠自身的受体感应外界的甲酰化多肽知道其迁移。作者认为，在不同的损伤类型，不同的组织，不同的时间，不同的淋巴细胞（包括中性粒细胞）的迁移所受到的信号都是特异的。因此，对这些信号的清晰分类能够帮助治疗各类型的炎症损伤性疾病yb-2337E 大鼠甘丙肽/甘丙素(GAL)ELISA kit 血清/组织/尿液yb-2338E 大鼠α葡萄糖苷酶(a-Glu)ELISA kit 血清/组织/尿液yb-2339E 大鼠破骨细胞分化因子(ODF)ELISA kit 血清/组织/尿液yb-2340E 大鼠Toll样受体9(TLR-9/CD289)ELISA kit   血清/组织/尿液yb-2341E 大鼠钩端螺旋体IgG(Lep IgG)ELISA kit   血清/组织/尿液yb-2342E 大鼠热休克因子1(HSF1)ELISA kit 血清/组织/尿液yb-2343E 大鼠β羟丁酸(βOHB)ELISA kit 血清/组织/尿液yb-2344E 大鼠细胞色素P450(CYP450)ELISA kit 血清/组织/尿液yb-2345E 大鼠生长激素释放肽ghrelin(GHRP-Ghrelin)ELISA kit   血清/组织/尿液yb-2346E 大鼠内脏脂肪特异性丝氨酸蛋白酶抑制剂(vaspin)ELISA kit   血清/组织/尿液yb-2347E 大鼠溴脱氧核苷尿嘧啶(BrdU)ELISA kit   血清/组织/尿液yb-2348E 大鼠转化生长因子β2(TGFβ2)ELISA kit 血清/组织/尿液yb-2349E 大鼠细胞色素P4502E1(CYP2E1)ELISA kit   血清/组织/尿液yb-2350E 大鼠α1微球蛋白(α1-MG)ELISA kit 血清/组织/尿液yb-2351E 大鼠单核细胞趋化蛋白4(MCP-4/CCL13)ELISA kit   血清/组织/尿液yb-2352E 大鼠过氧化物酶体增殖物激活受体α(PPAR-α)ELISA kit 血清/组织/尿液yb-2353E 大鼠钙调素(CAM)ELISA kit   血清/组织/尿液yb-2354E 大鼠载脂蛋白E(Apo-E)ELISA kit 血清/组织/尿液yb-2355E 大鼠网膜素(omentin)ELISA kit 血清/组织/尿液yb-2356E 大鼠孤腓肽(OFQ/N)ELISA kit 血清/组织/尿液yb-2357E 大鼠蛋白磷酸酶(PP)ELISA kit   血清/组织/尿液yb-2358E 大鼠硫氧还蛋白还原酶(TrxR)ELISA kit 血清/组织/尿液yb-2359E 大鼠硫氧化还原蛋白(Trx)ELISA kit 血清/组织/尿液yb-2360E 大鼠胶原酶II(Collagenase II)ELISA kit 血清/组织/尿液yb-2361E 大鼠髓系细胞触发受体-1(TREM-1)ELISA kit 血清/组织/尿液yb-2362E 大鼠胶原酶I(Collagenase I)ELISA kit 血清/组织/尿液yb-2363E 大鼠磷酸化蛋白激酶C(P-PKC)ELISA kit 血清/组织/尿液yb-2364E 大鼠磷酸化细胞外信号调节激酶(pERK)ELISA kit 血清/组织/尿液yb-2365E 大鼠组织蛋白酶K(cath-K)ELISA kit 血清/组织/尿液yb-2366E 大鼠巨噬细胞替代激活相关化学因子1(AmAC-1)ELISA kit   血清/组织/尿液yb-2367E 大鼠骨形成蛋白(BMPs)ELISA kit 血清/组织/尿液yb-2368E 大鼠视黄醇结合蛋白4(RBP-4)ELISA kit 血清/组织/尿液yb-2369E 大鼠6酮前列腺素F1a(6-keto-PGF1a)ELISA kit 血清/组织/尿液yb-2370E 大鼠戊糖素(Pentosidine)ELISA kit 血清/组织/尿液yb-2371E 大鼠晚期糖基化终末产物(AGEs)ELISA kit 血清/组织/尿液yb-2372E 大鼠中性粒细胞明胶酶相关脂质运载蛋白(NGAL)ELISA kit 血清/组织/尿液yb-2373E 大鼠幽门螺旋菌IgG(Hp-IgG)ELISA kit 血清/组织/尿液yb-2374E 大鼠雌激素受体(ER)ELISA kit   血清/组织/尿液yb-2375E 大鼠β-防御素(β-DF)ELISA kit 血清/组织/尿液yb-2376E 大鼠多巴胺D1受体(D1R)ELISA kit 血清/组织/尿液

来自美国的华人科学家Zheng-Rong Lu在国际学术期刊cancer research发表了一篇文章，他们针对β3整合素设计了siRNA并通过纳米颗粒进行体内转运能够显著抑制三阴性乳腺癌的生长，转移和复发，具有重要应用前景。 转移性乳腺癌是癌症导致女性死亡的第二大杀手，而三阴性乳腺癌是乳腺癌中具有高度侵袭性的一个亚型，到目前为止，仍缺少了解比较清楚的分子靶向目标以制定有效的靶向治疗策略。疾病复发，转移以及对药物的抵抗导致正常的化疗手段对于三阴性乳腺癌治疗不能达到有效的治疗效果。 之前有研究表明β3整合素与上皮细胞间充质转化和癌症转移具有紧密联系，因此研究人员提出利用纳米颗粒携带针对β3整合素设计的siRNA，以β3整合素为靶向目标进行三阴性乳腺癌治疗。 研究人员利用携带siRNA的纳米颗粒处理三阴性乳腺癌细胞，能够有效抑制β3整合素的表达，减弱TGFb介导的上皮细胞间充质转化和侵袭，重建TGFb介导的对癌细胞生长的抑制，并抑制3D类器官生长。研究人员又对该纳米颗粒进行了改造，增强了已发生EMT过程的细胞对siRNA的摄取能力。随后，研究人员利用静脉注射的方法将改造后携带siRNA的纳米颗粒注入小鼠静脉，结果发现小鼠原位肿瘤负荷减小，并且显著抑制了癌细胞的转移。除此之外，他们还对携带TGFb预处理的MDA-MB-231肿瘤的小鼠进行了该药物处理，肿瘤的转移，原位肿瘤切除后的癌症复发都受到显著抑制。 总的来说，这项研究表明利用纳米颗粒携带靶向β3整合素的siRNA治疗三阴性乳腺癌具有重要应用前景yb-2304E 大鼠脂多糖结合蛋白(LBP)ELISA kit   血清/组织/尿液yb-2305E 大鼠乙醇脱氢酶(ADH)ELISA kit 血清/组织/尿液yb-2306E 大鼠乙醛脱氢酶(ALDH)ELISA kit 血清/组织/尿液yb-2307E 大鼠可溶性CD14(sCD14)ELISA kit 血清/组织/尿液yb-2308E 大鼠缪勒管抑制物质/抗缪勒管激素(MIS/AMH)ELISA kit 血清/组织/尿液yb-2309E 大鼠雄激素(androgen)ELISA kit 血清/组织/尿液yb-2310E 大鼠Toll样受体4(TLR4)ELISA kit 血清/组织/尿液yb-2311E 大鼠多巴胺转运蛋白(DAT)ELISA kit 血清/组织/尿液yb-2312E 大鼠多巴胺D2受体(D2R)ELISA kit 血清/组织/尿液yb-2313E 大鼠β淀粉样蛋白1-42(Aβ1-42)ELISA kit 血清/组织/尿液yb-2314E 大鼠CD44分子(CD44)ELISA kit   血清/组织/尿液yb-2315E 大鼠8羟基脱氧鸟苷(8-OHdG)ELISA kit   血清/组织/尿液yb-2316E 大鼠白介素1受体拮抗剂(IL1Ra)ELISA kit 血清/组织/尿液yb-2317E 大鼠白介素1受体拮抗剂(IL1Ra)ELISA kit 血清/组织/尿液yb-2318E 大鼠胰岛素自身抗体(IAA)ELISA kit   血清/组织/尿液yb-2319E 大鼠抗核膜糖蛋白210抗体(gp210)ELISA kit 血清/组织/尿液yb-2320E 大鼠可溶性Toll样受体6(sTLR6)ELISA kit 血清/组织/尿液yb-2321E 大鼠可溶性Toll样受体2(sTLR2)ELISA kit 血清/组织/尿液yb-2322E 大鼠前列腺素F2α(PGF2α)ELISA kit 血清/组织/尿液yb-2323E 大鼠白三烯E4(LTE4)ELISA kit 血清/组织/尿液yb-2324E 大鼠尿激酶(UK)ELISA kit 血清/组织/尿液yb-2325E 大鼠凝血因子Ⅻ(FⅫ)ELISA kit   血清/组织/尿液yb-2326E 大鼠凝血因子ⅩⅢ(FⅩⅢ)ELISA kit 血清/组织/尿液yb-2327E 大鼠凝血因子Ⅲ(FⅢ)ELISA kit 血清/组织/尿液yb-2328E 大鼠载脂蛋白H(Apo-H)ELISA kit   血清/组织/尿液yb-2329E 大鼠白介素2受体(IL-2R)ELISA kit   血清/组织/尿液yb-2330E 大鼠肾上腺髓质素(ADM)ELISA kit   血清/组织/尿液yb-2331E 大鼠β内啡肽受体(β-EPR)ELISA kit 血清/组织/尿液yb-2332E 大鼠钙/钙调素依赖性蛋白激酶2(CAMK 2)ELISA kit 血清/组织/尿液yb-2333E 大鼠肝脂酶(HL)ELISA kit 血清/组织/尿液yb-2334E 大鼠烟碱型乙酰胆碱受体(N-AChR)ELISA kit 血清/组织/尿液yb-2335E 大鼠毒蕈碱型乙酰胆碱受体(M-AChR)ELISA kit   血清/组织/尿液yb-2336E 大鼠活化蛋白C(APC)ELISA kit 血清/组织/尿液

丝氨酸蛋白酶2(PRSS2)检测试剂盒适用生物     Homo sapiens (Human，人)    丝氨酸蛋白酶2(PRSS2)检测试剂盒    检测范围     0.781-50ng/mL     灵敏度     0.28ng/mL    样本类型     Serum, plasma and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法    丝氨酸蛋白酶2(PRSS2)检测试剂盒规格     96T    ELISA Kit for Protease, Serine 2 (PRSS2)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    丝氨酸蛋白酶2(PRSS2)检测试剂盒  Sample type     Serum, plasma and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.781-50ng/mL The standard curve concentrations used for the ELISA’s were 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.125ng/mL, 1.563ng/mL, 0.781ng/mL    Sensitivity     The minimum detectable dose 丝氨酸蛋白酶2(PRSS2)检测试剂盒of this kit is typically less than 0.28ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Protease, Serine 2 (PRSS2). No significant cross-reactivity 丝氨酸蛋白酶2(PRSS2)检测试剂盒or interference between Protease, Serine 2 (PRSS2) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Protease, Serine 2 (PRSS2) and the recovery rates were calculated by comparing the measured value to the expected amount of Protease, Serine 2 (PRSS2) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     88-101     94    EDTA plasma(n=5)     80-102     88    heparin plasma(n=5)     94-105     101    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Protease, Serine 2 (PRSS2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Protease, Serine 2 (PRSS2) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Protease, Serine 2 (PRSS2) and their serial dilutions. The results were demonstrated by the percentage of calculated 丝氨酸蛋白酶2(PRSS2)检测试剂盒concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     78-95%     93-101%     78-96%     84-98%    EDTA plasma(n=5)     80-89%     88-103%     86-94%     82-94%    heparin plasma(n=5)     96-105%     90-99%     98-105%     80-88%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, 丝氨酸蛋白酶2(PRSS2)检测试剂盒air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or丝氨酸蛋白酶2(PRSS2)检测试剂盒 sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been丝氨酸蛋白酶2(PRSS2)检测试剂盒 pre-coated with an antibody specific to Protease, Serine 2 (PRSS2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Protease, Serine 2 (PRSS2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Protease, Serine 2 (PRSS2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Protease, Serine 2 (PRSS2) in the samples is then determined by 丝氨酸蛋白酶2(PRSS2)检测试剂盒comparing the O.D. of the samples to the standard curve.

肺部激活调节趋化因子(PARC)检测试剂盒适用生物     Homo sapiens (Human，人)    肺部激活调节趋化因子(PARC)检测试剂盒    检测范围     78.13-5000pg/mL     灵敏度     30pg/mL    样本类型     Serum, plasma, tissue homogenates, cell culture supernates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     肺部激活调节趋化因子(PARC)检测试剂盒规格     96T    ELISA Kit for Pulmonary Activation Regulated Chemokine (PARC)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    肺部激活调节趋化因子(PARC)检测试剂盒 Sample type     Serum, plasma, tissue homogenates, cell culture supernates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     78.13-5000pg/mL The standard curve concentrations used for the ELISA’s were 5000pg/mL, 2500pg/mL, 1250pg/mL, 625pg/mL, 312.5pg/mL, 156.25pg/mL, 78.13pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 30pg/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Pulmonary Activation Regulated Chemokine (PARC). No significant cross-reactivity or interference肺部激活调节趋化因子(PARC)检测试剂盒 between Pulmonary Activation Regulated Chemokine (PARC) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Pulmonary Activation Regulated Chemokine (PARC) and the recovery rates were calculated by comparing the measured value to the expected肺部激活调节趋化因子(PARC)检测试剂盒 amount of Pulmonary Activation Regulated Chemokine (PARC) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     89-101     98    EDTA plasma(n=5)     96-103     101    heparin plasma(n=5)     92-104     99    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Pulmonary Activation Regulated Chemokine (PARC) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Pulmonary Activation Regulated 肺部激活调节趋化因子(PARC)检测试剂盒Chemokine (PARC) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Pulmonary Activation Regulated Chemokine (PARC) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     84-102%     98-105%     78-90%     79-98%    EDTA plasma(n=5)     78-89%     91-99%     88-96%     78-90%    heparin plasma(n=5)     80-91%     80-90%     94-102%     87-96%    StabilityThe stability of kit is determined 肺部激活调节趋化因子(PARC)检测试剂盒by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution肺部激活调节趋化因子(PARC)检测试剂盒. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Pulmonary Activation Regulated Chemokine (PARC). 肺部激活调节趋化因子(PARC)检测试剂盒Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Pulmonary Activation Regulated Chemokine (PARC). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Pulmonary Activation Regulated Chemokine (PARC), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Pulmonary Activation Regulated肺部激活调节趋化因子(PARC)检测试剂盒 Chemokine (PARC) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒适用生物     Homo sapiens (Human，人)    黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒    检测范围     78.13-5000pg/mL     灵敏度     33pg/mL    样本类型     Serum, plasma, tissue homogenates, urine and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒规格     96T    ELISA Kit for Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒Sample type     Serum, plasma, tissue homogenates, urine and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     78.13-5000pg/mL The standard curve concentrations used for the ELISA’s were 5000pg/mL, 2500pg/mL, 1250pg/mL, 625pg/mL, 312.5pg/mL, 156.25pg/mL, 78.13pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 33pg/mL.    SpecificityThis assay has high sensitivity 黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒and excellent specificity for detection of Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1). No significant cross-reactivity or interference between Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) and the recovery rates were calculated by comparing the measured value to the expected 黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒amount of Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     93-101     97    EDTA plasma(n=5)     97-105     101    heparin plasma(n=5)     90-104     93    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was 黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒assayed by testing samples spiked with appropriate concentration of Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     84-101%     81-98%     94-101%     80-103%    EDTA plasma(n=5)     94-101%     98-105%     96-103%     90-99%    heparin plasma(n=5)     81-93%     95-103%     96-104%     87-102%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested 黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒 in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mucosal Addressin Cell Adhesion 黏膜地址素细胞黏附分子(MAdCAM1)检测试剂盒Molecule 1 (MAdCAM1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

近日，来自美国NIH的科学家在国际学术期刊journal of hepatology在线发表了一项最新研究进展，他们发现利用姜黄素对肝癌细胞系进行处理可以特异性抑制癌症干细胞生长，并且对NF-kB和HDAC两条信号途径进行联合抑制可能是治疗具有不良预后的肝癌病人的有效策略。 癌症干细胞对包括肝细胞癌在内的多种癌症产生治疗抵抗具有重要促进作用。而在肝脏癌症干细胞中，NF-kB信号途径常发生突变。 在该项研究中，研究人员利用IKK 抑制因子姜黄素对不同肝细胞癌细胞系进行处理，表现出不同应答特征，根据敏感性不同可分为敏感性细胞系和抵抗性细胞系。在敏感性细胞系中，姜黄素介导的细胞死亡与NF-kB受抑制程度直接相关，并且姜黄素处理还会导致侧群细胞减少，克隆球形成能力下降，癌症干细胞标记表达下降以及肿瘤形成受到抑制，这都表明姜黄素可以导致癌症干细胞出现特异性缺失。与此类似，利用特异性多肽SN50抑制NF-kB或用针对p65的siRNA进行抑制均会抑制肿瘤细胞生长。而在抵抗性细胞系中，用姜黄素进行处理会促进细胞增殖，上调癌症干细胞标记的表达。 随后研究人员对敏感性细胞系中姜黄素对癌症干细胞的特异性抑制机制进行了研究，结果发现姜黄素的抑制作用与NF-kB介导的HDAC抑制有关，用I/II类HDAC抑制剂trichostatine处理抵抗性细胞会促进此类细胞对姜黄素的敏感性。 综上所述，这项研究表明阻断NF-kB可以特异性靶向癌症干细胞，并且NF-kB和HDAC两条途径的联合抑制对于治疗具有不良预后的肝癌病人可能具有潜在效果yb-2264E 大鼠转化生长因子β刺激蛋白22(TSC22)ELISA kit 血清/组织/尿液yb-2265E 大鼠白介素32(IL-32)ELISA kit 血清/组织/尿液yb-2266E 大鼠孕酮受体(PROGR)ELISA kit   血清/组织/尿液yb-2267E 大鼠白介素21(IL-21)ELISA kit   血清/组织/尿液yb-2268E 大鼠D-乳酸脱氢酶(D-LDH)ELISA kit   血清/组织/尿液yb-2269E 大鼠胸腺活化调节趋化因子(TARC/CCL17)ELISA kit 血清/组织/尿液yb-2270E 大鼠胆固醇(CH)ELISA kit 血清/组织/尿液yb-2271E 大鼠甘油三酯(TG)ELISA kit 血清/组织/尿液yb-2272E 大鼠低密度脂蛋白(LDL)ELISA kit   血清/组织/尿液yb-2273E 大鼠高密度脂蛋白(HDL)ELISA kit 血清/组织/尿液yb-2274E 大鼠孕酮受体(PGR)ELISA kit   血清/组织/尿液yb-2275E 大鼠血管紧张素Ⅱ转化酶(ACEⅡ)ELISA kit 血清/组织/尿液yb-2276E 大鼠血管紧张素Ⅰ转化酶(ACEⅠ)ELISA kit 血清/组织/尿液yb-2277E 大鼠促性腺激素释放激素受体(GnRHR)ELISA kit 血清/组织/尿液yb-2278E 大鼠磷酸化腺苷酸活化蛋白激酶(AMPK)ELISA kit 血清/组织/尿液yb-2279E 大鼠热休克蛋白47(HSP47)ELISA kit 血清/组织/尿液yb-2280E 大鼠内源性糖皮质激素(GC)ELISA kit 血清/组织/尿液yb-2281E 大鼠柠檬酸合酶(CS)ELISA kit 血清/组织/尿液yb-2282E 大鼠L-鼠乳酸脱氢酶(L-LDH) ELISA kit   血清/组织/尿液yb-2283E 大鼠脂酰辅酶A合成酶(ACS)ELISA kit 血清/组织/尿液yb-2284E 大鼠肉毒碱脂酰转移酶(CACT)ELISA kit 血清/组织/尿液yb-2285E 大鼠磷酸化乙酰辅酶A羧化酶(pACCase)ELISA kit 血清/组织/尿液yb-2286E 大鼠金属硫蛋白(MT)ELISA kit 血清/组织/尿液yb-2287E 大鼠心肌特异性肌钙蛋白T(cTnT)ELISA kit 血清/组织/尿液yb-2288E 大鼠乙酰胆碱酯酶(AChE)ELISA kit   血清/组织/尿液yb-2289E 大鼠糖缺失性转铁蛋白(CDT)ELISA kit   血清/组织/尿液yb-2290E 大鼠总胆汁酸(TBA)ELISA kit   血清/组织/尿液yb-2291E 大鼠β2微球蛋白(BMG/β2-MG)ELISA kit 血清/组织/尿液yb-2292E 大鼠视黄醇结合蛋白(RBP)ELISA kit 血清/组织/尿液yb-2293E 大鼠促性腺激素释放激素受体抗体(GNRHR-Ab)ELISA kit 血清/组织/尿液yb-2294E 大鼠血管性血友病因子裂解蛋白酶(ADAMTS13/vWF-cp)ELISA kit 血清/组织/尿液yb-2295E 大鼠主要碱性蛋白(MBP)ELISA kit   血清/组织/尿液yb-2296E 大鼠嗜酸性粒细胞阳离子蛋白(ECP)ELISA kit 血清/组织/尿液yb-2297E 大鼠钙调磷酸酶(CaN)ELISA kit   血清/组织/尿液yb-2298E 大鼠抑制素结合蛋白(INHBP)ELISA kit 血清/组织/尿液yb-2299E 大鼠抗甲状腺过氧化物酶抗体(TPO-Ab)ELISA kit 血清/组织/尿液yb-2300E 大鼠凋亡诱导因子(AIF)ELISA kit 血清/组织/尿液yb-2301E 大鼠抗双链DNA抗体/天然DNA抗体(dsDNA)ELISA kit   血清/组织/尿液yb-2302E 大鼠碱性磷酸酶(ALP)ELISA kit 血清/组织/尿液yb-2303E 大鼠血管生成素4(ANG-4)ELISA kit 血清/组织/尿液

许多研究发现蛋白质高度乙酰化与葡萄糖不耐受和胰岛素抵抗之间具有一定关联性，这表明调节乙酰化修饰组的酶可能在糖代谢的病理学过程中发挥重要作用。近日，来自美国的科学家在国际学术期刊diabetes在线发表了一项最新科研进展，他们发现去乙酰化酶sirt3在促进机体对葡萄糖的处理，增强线粒体功能，改善饮食诱导的胰岛素抵抗方面具有重要作用。 Sirt3是定位于线粒体中的NAD+依赖性去乙酰化酶，之前有研究发现sirt3在调节能量平衡方面具有重要作用。因此，在该项研究中，研究人员提出重要假设，通过基因删除sirt3造成线粒体蛋白乙酰化修饰水平的紊乱，可能会促进高脂饮食诱导的不良效应。 研究人员利用高胰岛素－正葡萄糖钳夹术实验首次发现由于骨骼肌葡萄糖摄取缺陷，导致sirt3缺失小鼠表现出胰岛素抵抗增加。随后，研究人员利用高脂饮食喂养的sirt3敲除小鼠肌肉纤维进行研究发现基于三羧酸循环底物的呼吸作用下降，而基于脂肪酸的呼吸作用增强，这表明细胞发生从以葡萄糖为能源向以脂肪酸为能源的转变。伴随着高脂饮食喂养的sirt3敲除小鼠骨骼肌葡萄糖摄取能力减弱，结合到线粒体的己糖激酶II（HKII）也发生减少，说明HKII活性出现下降。 这些结果表明在高脂饮食诱导的小鼠模型中，sirt3缺失会引起胰岛素刺激的骨骼肌葡萄糖摄取能力减弱，导致骨骼肌细胞对脂肪酸的依赖性增加，但在sirt3敲除的瘦小鼠中，胰岛素的作用并未受到损伤。 这项研究表明骨骼肌中的去乙酰化酶sirt3对于骨骼肌响应胰岛素作用以及改善高脂饮食诱导的胰岛素抵抗具有重要作用yb-2230E 大鼠Bcl-2相关X蛋白(BAX)ELISA kit 血清/组织/尿液yb-2231E 大鼠甘露糖结合蛋白/甘露糖结合凝集素(MBP/MBL)ELISA kit   血清/组织/尿液yb-2232E 大鼠白介素7(IL-7)ELISA kit 血清/组织/尿液yb-2233E 大鼠丝氨酸/苏氨酸蛋白磷酸酶(STK)ELISA kit   血清/组织/尿液yb-2234E 大鼠抗红细胞抗体(RBC)ELISA kit   血清/组织/尿液yb-2235E 大鼠CD3分子(CD3)ELISA kit 血清/组织/尿液yb-2236E 大鼠c-Jun氨基末端激酶(JNK)ELISA kit 血清/组织/尿液yb-2237E 大鼠高铁血红蛋白(MHB)ELISA kit   血清/组织/尿液yb-2238E 大鼠二胺氧化酶(DAO)ELISA kit   血清/组织/尿液yb-2239E 大鼠褪黑素(MT/MLT)ELISA kit   血清/组织/尿液yb-2240E 大鼠成纤维细胞生长因子10(FGF-10)ELISA kit 血清/组织/尿液yb-2241E 大鼠分泌型磷脂酶A2(sPLA2)ELISA kit   血清/组织/尿液yb-2242E 大鼠胞浆型磷脂酶A2(cPLA2)ELISA kit 血清/组织/尿液yb-2243E 大鼠Ⅰ型胶原交联羧基末端肽(ⅠCTP)ELISA kit   血清/组织/尿液yb-2244E 大鼠肌钙蛋白T(Tn-T)ELISA kit 血清/组织/尿液yb-2245E 大鼠CD8分子(CD8)ELISA kit 血清/组织/尿液yb-2246E 大鼠表皮生长因子受体(EGFR)ELISA kit 血清/组织/尿液yb-2247E 大鼠白介素2可溶性受体(IL-2sR)ELISA kit 血清/组织/尿液yb-2248E 大鼠轴突生长诱向因子1(Ntn1)ELISA kit 血清/组织/尿液yb-2249E 大鼠乳酸脱氢酶(LDH)ELISA kit 血清/组织/尿液yb-2250E 大鼠抗髓鞘相关糖蛋白抗体(MAG Ab)ELISA kit 血清/组织/尿液yb-2251E 大鼠Ⅰ型胶原C端肽(CTX-Ⅰ)ELISA kit   血清/组织/尿液yb-2252E 大鼠磷酸化核因子κB抑制蛋白α(pIKBα)ELISA kit 血清/组织/尿液yb-2253E 大鼠核因子κB(NF-κB)ELISA kit 血清/组织/尿液yb-2254E 大鼠树突状细胞表面特异性C型凝集素-细胞间黏附分子3结合非整合素分子(DC-SIGN/CD209) 血清/组织/尿液yb-2255E 大鼠Ⅰ型前胶原N端前肽(PⅠNP)ELISA kit 血清/组织/尿液yb-2256E 大鼠解整合素样金属蛋白酶9(ADAM9)ELISA kit   血清/组织/尿液yb-2257E 大鼠c-fos ELISA kit 血清/组织/尿液yb-2258E 大鼠c-jun ELISA kit   血清/组织/尿液yb-2259E 大鼠可溶性白介素6受体(sIL-6R)ELISA kit 血清/组织/尿液yb-2260E 大鼠吡啶酚(PYD)ELISA kit 血清/组织/尿液yb-2261E 大鼠β位淀粉样前体蛋白裂解酶2(BACE2)ELISA kit 血清/组织/尿液yb-2262E 大鼠骨碱性磷酸酶(BALP)ELISA kit 血清/组织/尿液yb-2263E 大鼠凝聚素(CLU)ELISA kit 血清/组织/尿液

窖蛋白(CAV1)检测试剂盒适用生物     Homo sapiens (Human，人)    窖蛋白(CAV1)检测试剂盒    检测范围     0.234-15ng/mL     灵敏度     0.11ng/mL    样本类型     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     窖蛋白(CAV1)检测试剂盒规格     96T    ELISA Kit for Caveolin 1 (CAV1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    窖蛋白(CAV1)检测试剂盒 Sample type     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.234-15ng/mL The standard curve concentrations used for the ELISA’s were 15ng/mL, 7.5ng/mL, 3.75ng/mL, 1.875ng/mL, 0.938ng/mL, 0.469ng/mL, 0.234ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.11ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Caveolin 1 (CAV1). No significant cross-reactivity or interference between Caveolin 1 (CAV1) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Caveolin 1 (CAV1) and the recovery rates were calculated by comparing the measured value to the expected amount of Caveolin 1 (CAV1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     80-93     86    EDTA plasma(n=5)     90-98     95    heparin plasma(n=5)     97-105     101    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Caveolin 1 (CAV1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Caveolin 1 (CAV1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Caveolin 1 (CAV1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     90-99%     94-101%     80-89%     81-99%    EDTA plasma(n=5)     88-99%     96-105%     84-92%     79-103%    heparin plasma(n=5)     95-103%     99-105%     86-95%     79-99%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is Sandwich 窖蛋白(CAV1)检测试剂盒enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Caveolin 1 (CAV1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Caveolin 1 (CAV1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Caveolin 1 (CAV1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Caveolin 1 (CAV1) in the samples is then determined by comparing the O.D. of the samples to the 窖蛋白(CAV1)检测试剂盒standard curve.

激肽释放酶4(KLK4)检测试剂盒适用生物     Rattus norvegicus (Rat，大鼠)    激肽释放酶4(KLK4)检测试剂盒    检测范围     0.156-10ng/mL     灵敏度     0.049ng/mL    样本类型     Serum, plasma and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     激肽释放酶4(KLK4)检测试剂盒规格     96T    ELISA Kit for Kallikrein 4 (KLK4)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Rattus norvegicus (Rat)    激肽释放酶4(KLK4)检测试剂盒  Sample type     Serum, plasma and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.049ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Kallikrein 4 (KLK4). No significant cross-reactivity or interference between Kallikrein 4 (KLK4) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Kallikrein 4 (KLK4) and the recovery rates were calculated by comparing the measured value to the expected amount of Kallikrein 4 (KLK4) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     89-98     94    EDTA plasma(n=5)     78-95     83    heparin plasma(n=5)     84-103     88    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Kallikrein 4 (KLK4) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Kallikrein 4 (KLK4) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Kallikrein 4 (KLK4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     96-104%     96-103%     99-105%     98-105%    EDTA plasma(n=5)     79-94%     83-91%     97-105%     83-103%    heparin plasma(n=5)     90-97%     93-101%     84-94%     86-93%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is 激肽释放酶4(KLK4)检测试剂盒Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Kallikrein 4 (KLK4). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Kallikrein 4 (KLK4). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Kallikrein 4 (KLK4), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Kallikrein 4 (KLK4) in the samples is then determined by comparing the O.D. of the samples to激肽释放酶4(KLK4)检测试剂盒 the standard curve.

胱天蛋白酶7(CASP7)检测试剂盒适用生物     Homo sapiens (Human，人)    胱天蛋白酶7(CASP7)检测试剂盒    检测范围     0.156-10ng/mL     灵敏度     0.055ng/mL    样本类型     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法    胱天蛋白酶7(CASP7)检测试剂盒规格     96T    ELISA Kit for Caspase 7 (CASP7)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    胱天蛋白酶7(CASP7)检测试剂盒Sample type     Serum, plasma, tissue homogenates, cell lysates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.055ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Caspase 7 (CASP7). No significant cross-reactivity or interference between Caspase 7 (CASP7) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Caspase 7 (CASP7) and the recovery rates were calculated by comparing the measured value to the expected amount of Caspase 7 (CASP7) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     95-103     99    EDTA plasma(n=5)     98-105     102    heparin plasma(n=5)     85-101     89    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Caspase 7 (CASP7) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Caspase 7 (CASP7) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Caspase 7 (CASP7) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     97-105%     80-88%     94-101%     80-89%    EDTA plasma(n=5)     80-99%     78-97%     88-98%     97-105%    heparin plasma(n=5)     88-99%     80-102%     99-105%     83-97%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. Test principleThe test principle applied in this kit is 胱天蛋白酶7(CASP7)检测试剂盒Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Caspase 7 (CASP7). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Caspase 7 (CASP7). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Caspase 7 (CASP7), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Caspase 7 (CASP7) in the samples is then determined by comparing the O.D. of the samples to胱天蛋白酶7(CASP7)检测试剂盒 the standard curve.

近日，由英国剑桥大学威康信托桑格研究所赠送的41万株突变小鼠胚胎干细胞，越过重洋，成功落户苏州大学剑桥—苏大基因组资源中心，该中心由此成为亚太地区仅有的一个突变小鼠胚胎干细胞资源库。突变小鼠胚胎干细胞是由桑格研究所领导的欧美联盟共同研发，全球仅有4份，其中3份分别在英国、德国和美国，最后1份能否落户中国，成为国内医学界关注的焦点。该干细胞资源库能最终落户苏州大学剑桥—苏大基因组资源中心，是国内乃至亚太地区医学界的喜事。在完成人类基因组的DNA测序后，探寻哺乳动物每个基因的功能成为生物医学领域的重要课题。科学家把与人类有超过90%基因同源性的小鼠作为研究对象，将小鼠胚胎干细胞进行单基因敲除后获得突变小鼠胚胎干细胞资源库，再将突变的小鼠胚胎干细胞培养成突变小鼠株，并对小鼠作表型分析，可系统性研究每个基因的功能、药物筛选和建立人类疾病模型。资源和数据共享是此次国际合作的意愿和目标。到2022年，苏州大学将承担500个小鼠基因的敲除和表型分析，并将数据与世界共享。剑桥—苏大基因组资源中心主任徐璎教授告诉记者，以往科研中需要用到这些突变小鼠胚胎干细胞时，需要从国外购买，进口时间大约需要6至8个月，大大影响了科研进程。“这些干细胞落户中国后，国内研究者1个月左右就可以收到相应的资源，大大缩短了资源进口的时间，降低了进口费用，为中国科研人员赢得更多的时间、更大的竞争力

在人类的癌症治疗方法中，特异性地靶向突变疗法引得了大肆赞扬，然而肿瘤细胞常常会对此上有政策，下有对策。为了研究清楚这个问题，来自加州大学圣迭戈医学院和Moores癌症中心的研究人员们发现了一种很有前景的联合疗法，来治疗最常见的大脑原发肿瘤-胶质母细胞瘤。这项发表在5月5号Oncotarget杂志上的研究发现，小鼠胶质母细胞瘤模型和病人来源的胶质母细胞组织（之后在实验室培养），均可以被三联抗癌药物有效治疗。这三种药分别为：一个是靶向上皮生长因子受体（EGFR）基因突变，一个是提高了癌症细胞的应激反应，另一个是损伤了肿瘤细胞的DNA。"研究胶质母细胞瘤的治疗方法就像是下棋游戏。医师每一步治疗或行动之后，肿瘤会有一个反招来对抗，"加州大学圣迭戈分校，神经外科学副教授，研究和学术发展副主席，此项研究的资深作者ClarkChen博士说。高达50％的胶质母细胞瘤有EGFR突变，从而使癌症细胞对环境因素进行的生长调节不敏感，最终使它们的生长失控。然而，高特异性的EGFR抑制剂对EGFR突变的胶质母细胞瘤并不特别有效。"当我们用EGFR抑制剂治疗胶质母细胞瘤细胞的时候，它们会开启另一个受体，从而绕过了对EGFR的需要，"Chen说。"任何有效的治疗方法，是需要一个战略性的举措，来设计一个可以将死的联合。"为了发展这样的一个战略，Chen和他的团队转向了PLK1，这个蛋白是调节胶质母细胞瘤的应激水平的，对这些细胞的存活十分重要。Chen和他的团队发现，对EGFR抑制剂抵抗的胶质母细胞瘤，仍然普遍地依赖于这个蛋白。在小鼠的胶质母细胞瘤模型，和病人胶质母细胞瘤中，单独使用EGFR抑制剂，PLK1抑制剂或者是目前的标准治疗药物（DNA损伤剂），都只能暂时地阻止肿瘤细胞的生长。但是，就像人类疾病一样，肿瘤终究又长回来了。然而，当将这三种药物联合使用，并没有发现肿瘤的复发。经过治疗的小鼠，经受住了这种联合治疗方案，且没有明显的副作用。"人们常常认为，如果我们找到了引起癌症的突变，并且抑制这个突变的功能，我们就可以治愈癌症，"加州大学圣迭戈分校，神经外科主任，此项研究的共同作者BobS.Carter博士说。"我们的研究表明，现实情况要复杂得多。我们的结果为如何利用生物的基本概念，来应对这项具有挑战性的复杂性，提供了蓝图。在这项研究中，用于小鼠模型的三种药物是：BI2536，PLK1抑制剂；Gefitnib，EGFR抑制剂和TMZ，胶质母细胞瘤的标准化疗药物。此项研究的作者指出，尽管三种药物联合治疗病人的安全性和副作用还不清楚，但在所有个体均有良好的耐受性。目前Gefitinib和TMZ治疗胶质母细胞瘤病人的临床安全性档案已经建立完善，PLK1抑制剂在目前的临床试验中有良好的耐受性（一个用于急性髓性白血病的药物已经进入了临床试验3期）

乳腺癌易感蛋白1(BRCA1)检测试剂盒适用生物     Homo sapiens (Human，人)    乳腺癌易感蛋白1(BRCA1)检测试剂盒   检测范围     0.156-10ng/mL     灵敏度     0.059ng/mL    样本类型     Tissue homogenates, cell lysates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     乳腺癌易感蛋白1(BRCA1)检测试剂盒规格     96T    ELISA Kit for Breast Cancer Susceptibility Protein 1 (BRCA1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    乳腺癌易感蛋白1(BRCA1)检测试剂盒Sample type     Tissue homogenates, cell lysates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     0.156-10ng/mL The standard curve concentrations used for the ELISA’s were 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 0.156ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.059ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Breast Cancer Susceptibility Protein 1 (BRCA1). No significant cross-reactivity or interference between Breast Cancer Susceptibility Protein 1 (BRCA1) and analogues was observed.乳腺癌易感蛋白1(BRCA1)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Breast Cancer Susceptibility Protein 1 (BRCA1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Breast Cancer Susceptibility Protein 1 (BRCA1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVStabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    乳腺癌易感蛋白1(BRCA1)检测试剂盒Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 乳腺癌易感蛋白1(BRCA1)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Breast Cancer Susceptibility Protein 1 (BRCA1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Breast Cancer Susceptibility Protein 1 (BRCA1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Breast Cancer Susceptibility Protein 1 (BRCA1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Breast Cancer Susceptibility Protein 1 (BRCA1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

γ-谷氨酰转移酶1(γGT1)检测试剂盒适用生物     Homo sapiens (Human，人)    γ-谷氨酰转移酶1(γGT1)检测试剂盒    检测范围     1.56-100ng/mL     灵敏度     0.59ng/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法    γ-谷氨酰转移酶1(γGT1)检测试剂盒规格     96T    ELISA Kit for Gamma-Glutamyltransferase 1 (gGT1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    γ-谷氨酰转移酶1(γGT1)检测试剂盒 Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     1.56-100ng/mL The standard curve concentrations used for the ELISA’s were 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.13ng/mL, 1.56ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.59ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Gamma-Glutamyltransferase 1 (gGT1). No significant cross-reactivity or interference between Gamma-Glutamyltransferase 1 (gGT1) and analogues was observed.γ-谷氨酰转移酶1(γGT1)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Gamma-Glutamyltransferase 1 (gGT1) and the recovery rates were calculated by comparing the measured value to the expected amount of Gamma-Glutamyltransferase 1 (gGT1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     99-105     102    EDTA plasma(n=5)     79-94     88    heparin plasma(n=5)     87-94     90    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Gamma-Glutamyltransferase 1 (gGT1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Gamma-Glutamyltransferase 1 (gGT1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Gamma-Glutamyltransferase 1 (gGT1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     80-97%     88-96%     81-92%     82-97%    EDTA plasma(n=5)     80-96%     80-105%     87-101%     82-104%    heparin plasma(n=5)     87-101%     83-90%     90-99%     99-105%    γ-谷氨酰转移酶1(γGT1)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. γ-谷氨酰转移酶1(γGT1)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Gamma-Glutamyltransferase 1 (gGT1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Gamma-Glutamyltransferase 1 (gGT1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Gamma-Glutamyltransferase 1 (gGT1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Gamma-Glutamyltransferase 1 (gGT1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

防御素β1(DEFβ1)检测试剂盒适用生物     Rattus norvegicus (Rat，大鼠)    防御素β1(DEFβ1)检测试剂盒    检测范围     46.88-3000pg/mL     灵敏度     17.29pg/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     防御素β1(DEFβ1)检测试剂盒规格     96T    ELISA Kit for Defensin Beta 1 (DEFb1)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Rattus norvegicus (Rat)    防御素β1(DEFβ1)检测试剂盒  Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     46.88-3000pg/mL The standard curve concentrations used for the ELISA’s were 3000pg/mL, 1500pg/mL, 750pg/mL, 375pg/mL, 187.5pg/mL, 93.75pg/mL, 46.88pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 17.29pg/mL.    防御素β1(DEFβ1)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Defensin Beta 1 (DEFb1). No significant cross-reactivity or interference between Defensin Beta 1 (DEFb1) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Defensin Beta 1 (DEFb1) and the recovery rates were calculated by comparing the measured value to the expected amount of Defensin Beta 1 (DEFb1) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     91-99     95    EDTA plasma(n=5)     85-97     89    heparin plasma(n=5)     78-98     85    防御素β1(DEFβ1)检测试剂盒PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Defensin Beta 1 (DEFb1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Defensin Beta 1 (DEFb1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Defensin Beta 1 (DEFb1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     79-102%     98-105%     92-103%     78-104%    EDTA plasma(n=5)     80-96%     98-105%     88-101%     98-105%    heparin plasma(n=5)     86-93%     80-104%     92-103%     90-98%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 防御素β1(DEFβ1)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Defensin Beta 1 (DEFb1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Defensin Beta 1 (DEFb1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Defensin Beta 1 (DEFb1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Defensin Beta 1 (DEFb1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

大肠癌（Colorectal cancer）是致死率很高的主要癌症类型之一。目前用于治疗大肠癌的方法主要是药物治疗，比如5-FU，以及irinotecan。然而，临床上接受药物治疗的晚期大肠癌患者五年存活率不足10%。常规性的抗癌药物的主要作用机理是引起DNA的损伤以及细胞的死亡，包括线粒体介导的内源性细胞凋亡以及死亡受体介导的外源性细胞凋亡。在肿瘤恶化过程中，新产生的肿瘤细胞经常会发生遗传或表观遗传上的突变，导致其对细胞凋亡不再敏感。因此，寻找其它导致癌细胞死亡的方式对于癌症的治疗十分重要。很久以来，细胞坏死都被认为是一类无规律的、被动性的细胞死亡方式，主要由炎症反应与组织损伤引发。最近几年的研究发现一些类型的坏死也是受到信号调控的。主要机理是：TNF-R1受到TNF-a的刺激激活，从而招募下游的丝氨酸激酶-RIP1与RIP3，进一步促发细胞坏死。在正常状态下这种程序化细胞坏死信号被细胞凋亡所抑制。在小鼠中，当caspase 8缺失后，小鼠由于RIP3导致的细胞坏死信号活化使得其在胚胎期致死。当额外敲除RIP-3后，小鼠便可正常发育。另外，在体外实验中caspase-8的抑制能够将TNF-a引导的细胞凋亡向细胞坏死方向转变，这一过程依赖RIP1, RIP3以及下游的效应分子MLKL。然而，目前对于DNA损伤如何引发细胞凋亡的机制仍不清楚。 最近，来自美国匹斯堡大学医学院的MF Brown等人在《nature cell death&disease》杂志发表了癌细胞坏死引发机制的研究结果。 首先，作者以人大肠癌细胞系HCT116为研究对象，人为敲除了细胞中的caspase 3蛋白。出人意料的是：敲除后的细胞系HCT116-/-对5-FU等癌症药物处理变得异常敏感（细胞生长受阻，细胞凋亡增多）。通过将肿瘤移植入小鼠体内，作者发现caspase 3敲除后的，在小鼠体内肿瘤耐药性相对于野生型（HCT116WT）下降明显。 之后，作者通过生化检测的手段发现HCT116-/-细胞与HCT116WT细胞在5-FU刺激下均发生了明显的caspase 9与caspase 7的切割活化。这一结果说明DNA损伤引起的细胞凋亡并没有收到影响。此外， HCT116-/-细胞在受到刺激后还出现了非细胞凋亡的现象：HMGB1的释放。对于细胞凋亡进行染色分析，作者发现HCT116-/-细胞与HCT116WT细胞在5-FU刺激下均发生了一定比例的细胞凋亡（Annexin-5+）,而且这一亚群可以被pan-caspase 抑制剂Z-VAD完全抑制。然而，HCT116-/-细胞还有相当一部分细胞亚群是坏死状态（Annexin-5-/PI+），这在野生型细胞中并没有出现，而且这一部分细胞不能被Z-VAD所抑制。 之前的研究发现，细胞坏死的信号是由一个经典的蛋白复合体介导的。这一复合体由caspase-8，RIP1，RIP3组成，可以被称为"坏死小体"。通过免疫共沉淀实验，作者发现在HCT116-/-细胞与HCT116WT细胞中，5-FU的刺激能够促进这一小体的形成，而在HCT116WT细胞中caspase 3也存在于这一复合体中。通过Z-VAD进行阻断，作者发现HCT116WT细胞的caspase 3不再存在于这一小体中，而展现出于与HCT116-/-细胞相似的表型。之后，作者向HCT116-/-细胞转入无酶活性的caspase-3，检测发现这一处理能够完全抑制HMGB1的释放与坏死的发生，这一结果说明caspase-3抑制坏死小体的发生不依赖于其酶活性。 之后，作者希望了解5-FU诱导的HCT116-/-细胞的坏死是否依赖caspase-8或RIP1，因此作者利用不同的手段（shRNA，dominant negative mutant，小分子抑制剂，siRNA）抑制RIP1与caspase-8的活性。检测结果发现，这些抑制的处理均能阻断5-FU刺激HCT116-/-细胞后引发的细胞坏死（Annexin-5/PI染色）与HGMB1的释放。之后，作者针对另外一株细胞系RKO利用shRNA方法进行caspase-3的敲低。结果与上述相同。 最终，作者证明了这一信号依赖于下游的活性氧反应。 总之，该文章第一次提出了caspase-3对于癌细胞的坏死具有负向的调控作用，因此在临床上结合DNA损伤药物与caspase-3抑制剂药物进行配合治疗有望诱导癌细胞发生坏死，从而达到最终清除癌细胞的目的

近日，来自法国的科学家在著名国际学术期刊Nature Medicine在线发表了他们的最新研究进展，他们发现IRF5与肥胖及胰岛素敏感性改变具有相关性，并通过敲除小鼠模型对其在肥胖及代谢中的作用进行了探讨。 内脏脂肪的积累与炎症增加以及代谢性疾病患病风险增加具有重要关联。但调节脂肪组织病理性扩张的分子机制一直不清楚。之前有研究表明干扰素调节因子5（IRF5）对于巨噬细胞向促炎症方向极化具有重要调节作用。 在该项研究中，研究人员发现IRF5缺失小鼠在高脂饮食刺激下，与野生型小鼠相比，其内脏脂肪的生长并没有明显变化，但其皮下脂肪组织表现出明显的扩张。通过对内脏脂肪进行分析，他们发现IRF5缺失小鼠其内脏脂肪中选择性激活的巨噬细胞出现明显的积累，并且高度的胶原沉积限制了脂肪细胞的生长，同时，与野生型小鼠相比，IRF5缺失小鼠的胰岛素敏感性得到了显著改善。 随后，研究人员利用肥胖人群进行了分析，发现IRF5的表达水平与内脏脂肪的胰岛素敏感性和胶原沉积呈负相关。研究人员对脂肪组织中对巨噬细胞进行了全基因组表达分析，结果表明TGFB1是IRF5的直接靶基因，IRF5能够介导对TGFB1表达的抑制作用。 这项研究揭示了IRF5在调节不同脂肪组织部位生长以及肥胖过程中胰岛素敏感性方面具有重要作用，抑制IRF5表达可能是促进代谢健康状态，改善肥胖及相关代谢紊乱的一条潜在途径

近日，来自哥本哈根大学的科学家在国际杂志Cell Stem Cell上刊登了最新的研究成果，他们鉴别出了一种机制，或可帮助解释某些干细胞如何选择变成既定的细胞类型，即干细胞会沿着DNA在精确的位点上结合特殊类型的蛋白质，当DNA上的特殊蛋白质被结合后，神秘“大门”就会开启使得特定的基因群进行表达来决定干细胞的新身份。研究者鉴别出了其中一种结合方式，即驱动细胞沿着特殊的路径“行进”从而促进细胞转变成为器官，比如肝脏和胰腺等；该研究或可帮助科学家们理解如何在实验室中制造产生产胰岛素细胞来进行1型糖尿病的治疗。Karen Schachter教授表示，这项研究中我们揭示了干细胞如何获取新身份标识的机制，干细胞可以对其周围环境产生反应，随后激活其余DNA上的特殊蛋白进行结合，最终开启遗传程序；研究者在培养基中加入了特殊的化合物来促进新型细胞的产生，由化合物介导的信息传递可以被少量蛋白质所解析，随后研究者在细胞的DNA上发现了由特殊化合物激活的蛋白质位点，同时他们利用额外的化合物重复了实验并且揭示了这种特殊反应发生的方式，此外研究者还对开启的基因进行了分类来帮助决定何时进行基因激活来决定细胞不同的命运。相关研究为发现正确的药物组合或化合物组合提供了一定的线索，其或帮助用于驱动干细胞转变为特殊的细胞类型。Nina Funa博士表示，目前我们无法解释这些化合物如何激活关键基因的表达，而这些基因可以给予细胞唯一性身份，原因或许是缺少可以重复实验结果的标准方法。这就好比我们使用预混合的面粉来制作蛋糕一样面临很多问题，如果我们用完了其中一种关键成分时我们就不知道如何来取代它的作用了，研究者认为本文研究可以帮助以多种可控的方式来产生许多功能性的细胞。研究者的最终目的就是理解干细胞如何进行自我选择，这将有助于研究者对干细胞身份的理解，从而为后期开发基于干细胞的新型疗法治疗疾病提供一定的希望和线索

集聚蛋白(AGRN)检测试剂盒适用生物     Homo sapiens (Human，人)    集聚蛋白(AGRN)检测试剂盒   检测范围     31.25-2000pg/mL     灵敏度     13.6pg/mL    样本类型     Serum, plasma, tissue homogenates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法    集聚蛋白(AGRN)检测试剂盒规格     96T    ELISA Kit for Agrin (AGRN)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     ybEB303Hu    Sample type     Serum, plasma, tissue homogenates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     31.25-2000pg/mL The standard curve concentrations used for the ELISA’s were 2000pg/mL, 1000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.25pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 13.6pg/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Agrin (AGRN). No significant cross-reactivity or interference between Agrin (AGRN) and analogues was observed.集聚蛋白(AGRN)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Agrin (AGRN) and the recovery rates were calculated by comparing the measured value to the expected amount of Agrin (AGRN) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     80-93     87    EDTA plasma(n=5)     97-105     102    heparin plasma(n=5)     88-96     92    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Agrin (AGRN) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Agrin (AGRN) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Agrin (AGRN) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     86-101%     80-104%     95-103%     93-101%    EDTA plasma(n=5)     79-90%     97-105%     90-104%     85-101%    heparin plasma(n=5)     90-98%     86-94%     83-95%     98-105%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    集聚蛋白(AGRN)检测试剂盒Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 集聚蛋白(AGRN)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Agrin (AGRN). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Agrin (AGRN). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Agrin (AGRN), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Agrin (AGRN) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

野鼠色基因相关蛋白(AGRP)检测试剂盒适用生物     Homo sapiens (Human，人)    野鼠色基因相关蛋白(AGRP)检测试剂盒  检测范围     7.81-500pg/mL     灵敏度     3.1pg/mL    样本类型     Serum, plasma and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     野鼠色基因相关蛋白(AGRP)检测试剂盒规格     96T    ELISA Kit for Agouti Related Protein (AGRP)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     ybEB302Hu    Sample type     Serum, plasma and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     7.81-500pg/mL The standard curve concentrations used for the ELISA’s were 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.25pg/mL, 15.63pg/mL, 7.81pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 3.1pg/mL.    野鼠色基因相关蛋白(AGRP)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Agouti Related Protein (AGRP). No significant cross-reactivity or interference between Agouti Related Protein (AGRP) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Agouti Related Protein (AGRP) and the recovery rates were calculated by comparing the measured value to the expected amount of Agouti Related Protein (AGRP) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     95-104     101    EDTA plasma(n=5)     83-99     94    heparin plasma(n=5)     87-101     95    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Agouti Related Protein (AGRP) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Agouti Related Protein (AGRP) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV野鼠色基因相关蛋白(AGRP)检测试剂盒LinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Agouti Related Protein (AGRP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     80-88%     79-101%     85-101%     94-101%    EDTA plasma(n=5)     82-90%     98-105%     95-103%     90-99%    heparin plasma(n=5)     80-92%     91-99%     80-89%     80-97%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 野鼠色基因相关蛋白(AGRP)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Agouti Related Protein (AGRP). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Agouti Related Protein (AGRP). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Agouti Related Protein (AGRP), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Agouti Related Protein (AGRP) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

不对称二甲基精氨酸(ADMA)检测试剂盒适用生物     General，通用    不对称二甲基精氨酸(ADMA)检测试剂盒    检测范围     12.35-1000ng/mL     灵敏度     4.61ng/mL    样本类型     Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.    实验时长     2.5h     实验方法     竞争抑制法     不对称二甲基精氨酸(ADMA)检测试剂盒规格     96T    ELISA Kit for Asymmetrical Dimethylarginine (ADMA)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     General    Product No.     ybEB301Ge    Sample type     Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.    Format     96-well strip plate    Assay length     2.5 hours    Detection range     12.35-1000ng/mL The standard curve concentrations used for the ELISA’s were 1000ng/mL, 333.33ng/mL, 111.11ng/mL, 37.04ng/mL, 12.35ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 4.61ng/mL.    不对称二甲基精氨酸(ADMA)检测试剂盒SpecificityThis assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA). No significant cross-reactivity or interference between Asymmetrical Dimethylarginine (ADMA) and analogues was observed.RecoveryMatrices listed below were spiked with certain level of recombinant Asymmetrical Dimethylarginine (ADMA) and the recovery rates were calculated by comparing the measured value to the expected amount of Asymmetrical Dimethylarginine (ADMA) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     78-92     87    EDTA plasma(n=5)     92-101     96    heparin plasma(n=5)     96-103     101    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Asymmetrical Dimethylarginine (ADMA) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Asymmetrical Dimethylarginine (ADMA) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV不对称二甲基精氨酸(ADMA)检测试剂盒LinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Asymmetrical Dimethylarginine (ADMA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     87-101%     85-97%     98-105%     93-101%    EDTA plasma(n=5)     86-96%     84-101%     91-98%     95-102%    heparin plasma(n=5)     85-102%     98-105%     83-92%     90-101%    StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    Reagent Diluent     1×300μL     Stop Solution     1×6mL    TMB Substrate     1×9mL     Instruction manual     1    Wash Buffer (30 × concentrate)     1×20mL    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 50μL standard or sample to each well.    And then add 50μL prepared Detection Reagent A immediately.    Shake and mix. Incubate 1 hour at 37oC;3. Aspirate and wash 3 times;4. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;5. Aspirate and wash 5 times;6. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;7. Add 50μL Stop Solution. Read at 450 nm immediately.不对称二甲基精氨酸(ADMA)检测试剂盒Test principleThis assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Asymmetrical Dimethylarginine (ADMA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Asymmetrical Dimethylarginine (ADMA) and unlabeled Asymmetrical Dimethylarginine (ADMA) (Standards or samples) with the pre-coated antibody specific to Asymmetrical Dimethylarginine (ADMA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample.

丝裂原激活蛋白激酶14(MAPK14)检测试剂盒适用生物     Homo sapiens (Human，人)    丝裂原激活蛋白激酶14(MAPK14)检测试剂盒    检测范围     1.56-100ng/mL     灵敏度     0.54ng/mL    样本类型     Tissue homogenates, cell lysates and other biological fluids.    实验时长     4.5h     实验方法     双抗夹心法     丝裂原激活蛋白激酶14(MAPK14)检测试剂盒规格     96T    ELISA Kit for Mitogen Activated Protein Kinase 14 (MAPK14)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     SEB206Hu    Sample type     Tissue homogenates, cell lysates and other biological fluids.    Format     96-well strip plate    Assay length     4.5 hours    Detection range     1.56-100ng/mL The standard curve concentrations used for the ELISA’s were 100ng/mL, 50ng/mL, 25ng/mL, 12.5ng/mL, 6.25ng/mL, 3.13ng/mL, 1.56ng/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 0.54ng/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Mitogen Activated Protein Kinase 14 (MAPK14). No significant cross-reactivity or interference between Mitogen Activated Protein Kinase 14 (MAPK14) and analogues was observed.PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mitogen Activated Protein Kinase 14 (MAPK14) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mitogen Activated Protein Kinase 14 (MAPK14) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CV丝裂原激活蛋白激酶14(MAPK14)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1×120μL     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    TMB Substrate     1×9mL     Stop Solution     1×6mL    Wash Buffer (30 × concentrate)     1×20mL     Instruction manual     1    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 100μL standard or sample to each well. Incubate 2 hours at 37oC;3. Aspirate and add 100μL prepared Detection Reagent A. Incubate 1 hour at 37oC;4. Aspirate and wash 3 times;5. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;6. Aspirate and wash 5 times;7. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;8. Add 50μL Stop Solution. Read at 450nm immediately. 丝裂原激活蛋白激酶14(MAPK14)检测试剂盒Test principleThe test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mitogen Activated Protein Kinase 14 (MAPK14). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Mitogen Activated Protein Kinase 14 (MAPK14). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mitogen Activated Protein Kinase 14 (MAPK14), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mitogen Activated Protein Kinase 14 (MAPK14) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

肾上腺髓质素(ADM)检测试剂盒适用生物     Homo sapiens (Human，人)    肾上腺髓质素(ADM)检测试剂盒   检测范围     12.35-1000pg/mL     灵敏度     4.35pg/mL    样本类型     Serum, plasma and other biological fluids.    实验时长     2.5h     实验方法     竞争抑制法    肾上腺髓质素(ADM)检测试剂盒规格     96T    ELISA Kit for Adrenomedullin (ADM)FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!Organism species     Homo sapiens (Human)    Product No.     CEA220Hu    Sample type     Serum, plasma and other biological fluids.    Format     96-well strip plate    Assay length     2.5 hours    Detection range     12.35-1000pg/mL The standard curve concentrations used for the ELISA’s were 1000pg/mL, 333.33pg/mL, 111.11pg/mL, 37.04pg/mL, 12.35pg/mL    Sensitivity     The minimum detectable dose of this kit is typically less than 4.35pg/mL.    SpecificityThis assay has high sensitivity and excellent specificity for detection of Adrenomedullin (ADM). No significant cross-reactivity or interference between Adrenomedullin (ADM) and analogues was observed.肾上腺髓质素(ADM)检测试剂盒RecoveryMatrices listed below were spiked with certain level of recombinant Adrenomedullin (ADM) and the recovery rates were calculated by comparing the measured value to the expected amount of Adrenomedullin (ADM) in samples. Matrix     Recovery range (%)     Average(%)    serum(n=5)     90-97     93    EDTA plasma(n=5)     78-97     93    heparin plasma(n=5)     78-93     83    PrecisionIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Adrenomedullin (ADM) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Adrenomedullin (ADM) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CVInter-Assay: CVLinearityThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Adrenomedullin (ADM) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected. Sample     1:2     1:4     1:8     1:16    serum(n=5)     93-101%     78-97%     87-98%     85-102%    EDTA plasma(n=5)     97-105%     79-91%     88-96%     87-95%    heparin plasma(n=5)     80-91%     94-102%     92-101%     78-94%    肾上腺髓质素(ADM)检测试剂盒StabilityThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.Reagents and materials providedReagents     Quantity     Reagents     Quantity    Pre-coated, ready to use 96-well strip plate     1     Plate sealer for 96 wells     4    Standard     2     Standard Diluent     1×20mL    Detection Reagent A     1     Assay Diluent A     1×12mL    Detection Reagent B     1×120μL     Assay Diluent B     1×12mL    Reagent Diluent     1×300μL     Stop Solution     1×6mL    TMB Substrate     1×9mL     Instruction manual     1    Wash Buffer (30 × concentrate)     1×20mL    Assay procedure summary1. Prepare all reagents, samples and standards;2. Add 50μL standard or sample to each well.    And then add 50μL prepared Detection Reagent A immediately.    Shake and mix. Incubate 1 hour at 37oC;3. Aspirate and wash 3 times;4. Add 100μL prepared Detection Reagent B. Incubate 30 minutes at 37oC;5. Aspirate and wash 5 times;6. Add 90μL Substrate Solution. Incubate 15-25 minutes at 37oC;7. Add 50μL Stop Solution. Read at 450 nm immediately.肾上腺髓质素(ADM)检测试剂盒Test principleThis assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Adrenomedullin (ADM) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Adrenomedullin (ADM) and unlabeled Adrenomedullin (ADM) (Standards or samples) with the pre-coated antibody specific to Adrenomedullin (ADM). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Adrenomedullin (ADM) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Adrenomedullin (ADM) in the sample.

利用CRISPR/Cas系统进行基因组编辑可以对小鼠受精卵中的小鼠基因组进行直接地修饰，从而开发出高效、快速、一步法产生，且不携带胚胎干细胞的基因敲除小鼠，相比有针对性地进行靶向基因剔除，即进行靶向基因插入的技术而言，这种利用CRISPR/Cas系统介导的基因组编辑技术目前而言仍然是一项比较艰巨的任务。近日，来自东京医科牙科大学的研究人员在国际杂志Genome Biology上刊登了其最新的研究成果，他们通过开发一种高效的CRISPR/Cas系统克服了当前的研究障碍，这种技术可以实现较长基因盒的靶向插入，包括在受精卵中以高达50%的效率将增强绿色荧光蛋白插入到小鼠的基因组中。文章中，研究人员再现了CRISPR/Cas系统的天然状态，其包括三种组分：Cas9蛋白、CRISPR RNA（crRNA）以及反义激活crRNA，这种新型系统取代了常见的利用两种组分的系统，即Cas9 mRNA和单一导向RNA（sgRNA）；这种改进的CRISPR/Cas系统可以提供便利高效的基因修饰，同时也可以成功传递给后代。在未来这种改进后的CRISPR/Cas或许可以进行多种用途，包括开发可以模拟人类疾病的人源化小鼠、药物代谢研究、免疫及感染性疾病的研究；研究者表示，准确的靶向插入将可以有效改善病人进行基因疗法的安全性，而这种改进的系统或许也可以用于其它研究，比如畜牧业生产等

猪的皮肤细胞可以帮助开发治疗人类破坏性神经疾病的新型疗法，近日来自乔治亚大学的科学家通过研究成功将猪机体的诱导多能干细胞转化成了诱导神经干细胞，相关研究发表于国际杂志Stem Cells and Development上；该研究基于人类机体神经干细胞发育的相同过程，或可帮助理解神经变性疾病的发病机制，比如阿尔兹海默氏症、帕金森疾病等。研究者Steven Stice表示，我们首次真正地进行了动物蓝图的规划，利用该蓝图可以模拟人类机体的疾病过程，从而促进我们更为清楚地分析理解人类神经性疾病的发病机制；此前研究中，研究人员会停止利用初始细胞群进行研究，而以猪胚胎干细胞进行研究，这种干细胞是非常难得的来源，有时其会分化形成意想不到的细胞类型，包括神经元细胞、肝脏细胞，甚至是肌肉细胞等。本文研究中研究者阐明了猪皮肤干细胞的特性，同时诱导其分化成为神经干细胞，猪皮肤干细胞所具有的特殊标志物也确定了其很有可能被诱导分化成为神经细胞；最初研究者认为，成年个体的大脑不可能进行干细胞疗法治疗，而且其也不能够产生新的神经元来进行再生。当前的问题是，将诱导多能干细胞置于大脑后，其有可能会转变成为任何每一种类型的细胞，随后就会形成肿瘤，因此诱导其成为神经干细胞后其就只能形成不同的神经细胞类型。研究者表示，首先我们从猪的皮肤中进行细胞的提取，并且将其重编程形成诱导多能干细胞，随后在用于细胞鉴定的蛋白标记技术的帮助下将这些皮肤干细胞诱导成为神经元细胞，这或许可以帮助产生数以百万计的神经元细胞，先进的技术使得研究从试验台转向了临床研究或许不再是一个梦，然而在过去研究者不得不进行大量的检测来观察诱导后的神经元是否可以发挥功能，而如今由于研究者在猪体内模拟了人类细胞的相同发育途径，过去的问题将会迎刃而解。最后研究者表示，总之我们最终的目标就是利用新技术来诱导产生更多的神经干细胞，从而开发新型的靶向性疗法治疗人类的神经变性疾病

干细胞（stem cell）是一类具有自我复制能力的多潜能细胞。在一定条件下，它可以分化成多种功能细胞。同时，干细胞（Stem Cell）还是一种未充分分化，尚不成熟的细胞，具有再生各种组织器官和人体的潜在功能。在最新发表在国际学术期刊molecular cell的一项研究中，来自salk institute的科学家们发现了影响干细胞生长的关键信号途径，对于再生器官和组织研究具有重要意义。 研究人员指出，虽然目前已经知道wnt和activin两条关键途径对于干细胞生长分化为特定成熟细胞具有重要作用，但这两条途径究竟如何共同作用调控干细胞命运，其中的机制仍不清楚。 在该项研究中，研究人员发现这两条关键途径在机制上具有互补性，并能够激活大约200个参与干细胞分化的重要基因，这些激活的基因主要参与干细胞向特定组织分化的起始步骤。在调节基因转录激活的过程中，wnt信号途径主要负责基因复制和激活的起始，而activin信号途径则会进一步促进这一过程，提高基因复制和激活效率。同时，wnt和activin信号刺激的先后顺序非常重要，细胞在接受wnt信号刺激之前，activin信号并不能开启基因的转录激活。通过进一步研究，研究人员还惊奇地发现，wnt和activin信号途径还与调控组织器官生长的hippo信号途径具有重要关联，并且activin与hippo途径关键分子yap具有相反的功能，两者都参与转录延伸过程。 研究人员最后指出，很多研究已经证明wnt和activin信号途径都在癌症发生转移过程中发挥重要作用，虽然在该项研究中，他们发现wnt和activin信号途径能够协同调节干细胞分化，但干细胞和肿瘤的生存环境不同，表达的基因也存在很大差异，wnt和activin信号途径是否也在肿瘤细胞中发挥协同调控作用仍未可知，需要进一步的研究来进行探究证明